ascopubs.org

Second primary malignancy (SPM) in patients (pts) with multiple myeloma (MM) receiving chimeric antigen receptor T-cell (CAR T) therapy or other systemic anticancer therapy ...

Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM). Cumulative incidence (%) and 95% CI of SPM at 24 months.
Nature

Second primary malignancies after treatment for malignant lymphoma

To determine the incidence and possible causes of second primary malignancies after treatment for Hodgkin's and Non-Hodgkin's lymphoma (HL and NHL). A cohort of 3764 consecutive patients diagnosed ...
ascopubs.org

Risk of second primary malignancy (SPM) and survival of adult patients with polycythemia vera (PV): A U.S. population-based study.

Overall survival (OS) and baseline disease characteristics in MDS patients with primary HMA failure in a randomized, controlled, phase III study of rigosertib. This is an ASCO Meeting Abstract from ...